Literature DB >> 12805416

Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.

Erwei Song1, Sang-Kyung Lee, Derek M Dykxhoorn, Carl Novina, Dong Zhang, Keith Crawford, Jan Cerny, Phillip A Sharp, Judy Lieberman, N Manjunath, Premlata Shankar.   

Abstract

Small interfering RNAs (siRNAs) can induce potent gene silencing by degradation of cognate mRNA. However, in dividing cells, the silencing lasts only 3 to 7 days, presumably because of siRNA dilution with cell division. Here, we investigated if sustained siRNA-mediated silencing of human immunodeficiency virus type 1 (HIV-1) is possible in terminally differentiated macrophages, which constitute an important reservoir of HIV in vivo. CCR5, the major HIV-1 coreceptor in macrophages, and the viral structural gene for p24 were targeted either singly or in combination. When transfected 2 days prior to infection, both CCR5 and p24 siRNAs effectively reduced HIV-1 infection for the entire 15-day period of observation, and combined targeting of both genes abolished infection. To investigate whether exogenously introduced siRNA is maintained stably in macrophages, we tested the kinetics of siRNA-mediated viral inhibition by initiating infections at various times (2 to 15 days) after transfection with CCR5 and p24 siRNAs. HIV suppression mediated by viral p24 siRNA progressively decreased and was lost by day 7 posttransfection. In contrast, viral inhibition by cellular CCR5 knockdown was sustained even when transfection preceded infection by 15 days, suggesting that the continued presence of target RNA may be needed for persistence of siRNA. The longer sustenance of CCR5 relative to p24 siRNA in uninfected macrophages was also confirmed by detection of internalized siRNA by modified Northern blot analysis. We also tested the potential of p24 siRNA to stably silence HIV in the setting of an established infection where the viral target gene is actively transcribed. Under these circumstances, long-term suppression of HIV replication could be achieved with p24 siRNA. Thus, siRNAs can induce potent and long-lasting HIV inhibition in nondividing cells such as macrophages.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805416      PMCID: PMC164789          DOI: 10.1128/jvi.77.13.7174-7181.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  RNA interference--2001.

Authors:  P A Sharp
Journal:  Genes Dev       Date:  2001-03-01       Impact factor: 11.361

Review 2.  New targets for inhibitors of HIV-1 replication.

Authors:  J P Moore; M Stevenson
Journal:  Nat Rev Mol Cell Biol       Date:  2000-10       Impact factor: 94.444

3.  Expanding small RNA interference.

Authors:  Thomas Tuschl
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

4.  Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans.

Authors:  R F Ketting; S E Fischer; E Bernstein; T Sijen; G J Hannon; R H Plasterk
Journal:  Genes Dev       Date:  2001-10-15       Impact factor: 11.361

5.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

6.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

7.  Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy.

Authors:  S Sonza; H P Mutimer; R Oelrichs; D Jardine; K Harvey; A Dunne; D F Purcell; C Birch; S M Crowe
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

Review 8.  RNA interference: advances and questions.

Authors:  Elisabetta Ullu; Appolinaire Djikeng; Huafang Shi; Christian Tschudi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-01-29       Impact factor: 6.237

9.  The role of CC chemokine receptor 5 in antiviral immunity.

Authors:  Anneline Nansen; Jan Pravsgaard Christensen; Susanne Ørding Andreasen; Christina Bartholdy; Jeanette Erbo Christensen; Allan Randrup Thomsen
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

10.  Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference.

Authors:  John Capodici; Katalin Karikó; Drew Weissman
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

View more
  93 in total

Review 1.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

Review 2.  Diversifying microRNA sequence and function.

Authors:  Stefan L Ameres; Phillip D Zamore
Journal:  Nat Rev Mol Cell Biol       Date:  2013-06-26       Impact factor: 94.444

3.  Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV.

Authors:  Sang-Kyung Lee; Derek M Dykxhoorn; Priti Kumar; Shahin Ranjbar; Erwei Song; Laura E Maliszewski; Vanessa François-Bongarçon; Anne Goldfeld; N Manjunath Swamy; Judy Lieberman; Premlata Shankar
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

4.  Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression.

Authors:  Gang Peng; Teresa Greenwell-Wild; Salvador Nares; Wenwen Jin; Ke Jian Lei; Zoila G Rangel; Peter J Munson; Sharon M Wahl
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

5.  Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches.

Authors:  Leonid Gitlin; Jeffrey K Stone; Raul Andino
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes.

Authors:  Keigo Machida; George McNamara; Kevin T-H Cheng; Jeffrey Huang; Chun-Hsiang Wang; Lucio Comai; Jing-Hsiung James Ou; Michael M C Lai
Journal:  J Immunol       Date:  2010-10-25       Impact factor: 5.422

Review 7.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

8.  Drosha as an interferon-independent antiviral factor.

Authors:  Jillian S Shapiro; Sonja Schmid; Lauren C Aguado; Leah R Sabin; Ari Yasunaga; Jaehee V Shim; David Sachs; Sara Cherry; Benjamin R tenOever
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

9.  Importin 7 may be dispensable for human immunodeficiency virus type 1 and simian immunodeficiency virus infection of primary macrophages.

Authors:  Steven P Zielske; Mario Stevenson
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.